Agenus Inc. (NASDAQ:AGEN) Receives $10.00 Average Price Target from Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have earned a consensus rating of “Hold” from the six research firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $10.00.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research report on Wednesday, January 22nd.

Agenus Stock Down 4.1 %

Agenus stock opened at $3.74 on Tuesday. Agenus has a 52-week low of $2.50 and a 52-week high of $19.69. The firm has a market cap of $87.74 million, a PE ratio of -0.33 and a beta of 1.30. The company’s 50 day moving average is $3.27 and its two-hundred day moving average is $4.29.

Institutional Investors Weigh In On Agenus

A number of hedge funds and other institutional investors have recently modified their holdings of AGEN. EP Wealth Advisors LLC acquired a new position in shares of Agenus during the third quarter worth $55,000. Point72 DIFC Ltd lifted its holdings in Agenus by 380.0% during the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after buying an additional 11,542 shares during the last quarter. Apollon Wealth Management LLC acquired a new position in shares of Agenus during the 4th quarter worth about $55,000. HighTower Advisors LLC increased its holdings in shares of Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 7,530 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its position in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock worth $151,000 after acquiring an additional 9,422 shares in the last quarter. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.